tesmilifene Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Tesmilifene, also known as N,N-diethyl-2-(4-phenylmethyl)ethanamine (DPPE), is a small-molecule antineoplastic drug and chemopotentiator that was under development by YM BioSciences for the treatment of breast cancer in the 2000s but was never marketed. It reached phase III clinical trials for advanced/metastatic breast cancer before development was discontinued.   Wikipedia

Chemistry

  • SMILES: CCN(CC)CCOc1ccc(Cc2ccccc2)cc1
  • InChIKey: NFIXBCVWIPOYCD-UHFFFAOYSA-N
  • Mol. Mass: 283.41
  • ALogP: 4.0
  • ChEMBL Molecule:
    tesmilifene  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine | 1,2-dipalmitoyl-3-phosphatidylethanolamine | 1,2-dipalmitoyl-3-phosphatidylethanolamine, ion(1-) | 1,2-dipalmitoyl-3-phosphatidylethanolamine, (+-)-isomer | 1,2-dipalmitoyl-3-phosphatidylethanolamine, (r)-isomer | 1,2-dipalmitoyl-rac-glycerophosphoethanolamine | 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine | (2-(4-benzylphenoxy)ethyl)diethylamine | bzphoet-diethylammonium chloride | depmpe | dhpe | dipalmitoyl cephalin | dipalmitoyl phosphatidylethanolamine | dppe | dppe hydrochloride | ethanamine, n,n-diethyl-2-(4-(phenylmethyl)phenoxy)-, (2ar-(2aalpha,4beta,4abeta,6beta,9alpha(alphar*,betas*),11alpha,12alpha,12aalpha,12balpha))- | n,n-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine | n,n-diethyl-2-(4-(phenylmethyl)phenoxy)ethanamine | n,n-diethyl-2-((4-phenylmethyl)phenoxy)-ethanamine hydrochloride | n,n-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine hydrochloride | n,n-diethyl-2-(4-(phenylmethyl)phenoxy)ethanamine hydrochloride | phosphatidylethanolamine dipalmitoate | tesmilifene | tesmilifene hydrochloride | ymb 1002

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Breast Neoplasms (Phase 3)

Neoplasm Metastasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue